创模生物科技(北京)有限公司

CN / En

NEWS

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-18 14:39
  • Views:

(Summary description)With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality

InnoModels Biotechnology ELISpot platform: a powerful tool to precisely analyze the immune response

(Summary description)With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality

  • Categories:Company news
  • Author:InnoModels
  • Origin:InnoModels
  • Time of issue:2024-10-18 14:39
  • Views:
Information

With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Biotechnology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality.
1. Platform Introduction
InnoModels' ELISpot platform is a cellular detection technology that combines high sensitivity and high precision. By detecting cytokines secreted by individual cells, it is able to analyze in detail the response and function of immune cells such as T cells and B cells, and has demonstrated excellent performance in the study of cytotoxic T lymphocytes (CTLs) and their immune response.
2. Core Advantages
Multiple CTL stimulation methods: The platform provides multiple CTL stimulation methods, including in vitro specific antigen presentation using human or mouse peripheral blood mononuclear cells (PBMCs) or spleen immune cells. It is also possible to analyze peripheral blood or spleen cells after immunization in immunologically sound mice to ensure comprehensive and accurate results.
Specific MHC antigen presentation: The platform utilizes a specific MHC antigen presentation pathway to activate CTLs, ensuring that CTL activation is strictly dependent on the presence of the appropriate MHC molecule, thus avoiding non-specific activation in the event of an MHC mismatch and improving the reliability of experimental results.
Highly Sensitive Detection: The ELISpot platform is known for its high sensitivity, capable of detecting even low levels of CTL responses. This enables researchers to accurately measure and analyze CTL activity in different biological samples, providing a powerful tool for in-depth study of immune responses.
Quantitative and Qualitative Analysis: The platform provides the ability to quantitatively and qualitatively analyze CTL production levels, allowing researchers to comprehensively assess the quantity and quality of CTL responses. This analytical capability is critical for understanding and monitoring the immune response process, and plays a particularly important role in cancer vaccine research and tumor immunotherapy development.

 


3. Application Areas
InnoModels' ELISpot platform is widely used in tumor vaccine research, immunomodulatory drug development, and individualized medicine. Through the platform, researchers can deeply explore the mechanism of CTL in anti-tumor immunity, evaluate the effectiveness of tumor vaccines, and screen potential immunomodulatory drugs. In addition, the platform is also applicable to the analysis of clinical patient samples, providing a scientific basis for the development of individualized medical treatment plans.
4、Summary and Prospect
The emergence of the InnoModels Biotechnology ELISpot platform has revolutionized the field of immunology research. Its high sensitivity, multifunctionality and wide range of application prospects have made the platform an indispensable research tool for researchers. With the continuous development and improvement of the technology, it is believed that the ELISpot platform will play an even more important role in future scientific research and clinical applications, and contribute more to the cause of human health.

Keyword:

In the vast field of oncology and tumor immunopharmacodynamics research, InnoModels Biotechnology (Beijing) Ltd. has become a leader in the industry with its outstanding innovation ability and profound scientific research background. This company, co-founded by scientists from Novo Nordisk China R&D Center, Sino-US Crown and Shanghai Jiao Tong University Institute of Immunology, has been committed to building a stable domestic platform of humanized mouse models of the immune system (HIS) and human tumor xenografts (PDX) since its establishment in 2020, to provide new drug discovery and development companies, translational medicine researchers, and tumor patients with new-generation laboratory animal models for new drug discovery companies, translational medicine researchers, and tumor patients
In recent years, many breakthroughs have been made in the field of biomedical research, among which iHuPBMC-T technology is undoubtedly a shining star. As an innovative platform built by InnoModels Biotechnology (Beijing) Co., Ltd, iHuPBMC-T, with its unique technological advantages, shows great potential in optimizing the reconstruction of human peripheral blood single nucleated cell (PBMC) model and immuno-oncology research.
Recently, InnoModels Biotechnology (Beijing) Co., Ltd. has made a major breakthrough in the field of pharmaceutical technology, and successfully obtained a patent entitled “Method and application for the detection of immune system rebuilding ability of PBMC”. This patent not only adds a new footnote to the R&D strength of InnoModels Biotechnology in the field of biomedicine, but also provides a strong technical support for the promotion of drug research and development and the establishment of humanized experimental animal models
With the rapid development of biotechnology, the in-depth study of the immune system has become the key to new drug discovery, disease diagnosis and treatment. InnoModels Bio-technology (Beijing) Co., Ltd. provides strong support for researchers with its profound scientific background and advanced technology platform. Among them, the ELISpot platform of InnoModels Biotechnology has made a name for itself in the field of immunology research with its high sensitivity and multi-functionality
InnoModels' ADCC platform plays a pivotal role in advancing cancer treatment, and its unique technological advantages and innovative concepts have brought about a far-reaching impact on the field of tumor immunotherapy. The following is a detailed introduction of how the platform promotes the advancement of cancer treatment
In the field of tumor immunotherapy, complement-dependent cytotoxicity (CDC), as an important therapeutic mechanism, is gradually showing its great potential and value. In order to explore this mechanism more deeply, with its profound accumulation in the field of oncology and tumor immunopharmacodynamics CRO services, InnoModels Biotechnology (Beijing) Co., Ltd. has launched the CDC in vitro immune-tumor cell co-culture killing experimental platform, which provides researchers with a powerful and precise tool to help innovate cancer treatment
Previous page
1
2
43
  • Tel 15010000264
  • E-mail limy@imodels.tech
  • Tel 13810723384
  • Top

InnoModels Biotechnology (Beijing) Co., Ltd.

TEL:15010000264        13810723384

Address:Building 14, Life Valley, Shuangying West Road, Changping District, Beijing

Chuangmo Biotechnology (Beijing) Co., Ltd. Beijing ICP 222*** 98-1 Website Construction: China Enterprise Power Beijing Second Branch Company

北京中因科技有限公司

创模生物科技(北京)有限公司